Home
| Log in or Sign Up for full access
| Tracked Organizations
| Recent Tracked Activities
Recent Activities
Activities between Nov. 15, 2024, 7:35 p.m. and Nov. 22, 2024, 7:35 p.m.
from: Life Science Research Tools And Diagnostics.
Click on a document link to see the original source document.
Click on the name of an organization to see more organization linkages and timelines.
Document Date: Nov. 18, 2024, noon / Source: PR Newswire
Activity Class: PartnershipActivity
/ Region: Minneapolis
Partnership:
- ALZpath
/ Industry: Life Sciences And Technology
- Bio-Techne
/ Industry: Biotech And Technology, Diagnostics And Medical Devices and 4 more
- ALZpath
/ Industry: Life Sciences And Technology
- Bio-Techne Corporation
/ Industry: Biopharmaceutical And Biotech Industry, Biotech And Technology and 5 more
Document Extract: The ALZpath pTau217 (phosphorylated Tau217) antibody is the leading antibody used to detect the pTau217 biomarker. Increased levels of pTau217 are associated with amyloid plaques and tau tangles, the hallmark features of Alzheimer's disease. Running the Simple Plex Human Phospho Tau 217 ALZpath Assay on the Ella system will enable researchers to detect the pTau217 signal in less invasive sample collection types, like plasma samples, in just 90 minutes with no manual intervention, increasing efficiency, scalability, and precision while providing the necessary data to help accelerate clinical decisions. " Our partnership with ALZpath represents a major step forward in our commitment to advancing neurodegenerative disease research ," said Will Geist, President of Bio-Techne's Protein Sciences Segment. " We 're excited to see the impact that this easy-to-use, hands-free platform will have on advancing research in this critical field ."
Document Source: https://www.prnewswire.com/news-releases/bio-techne-and-alzpath-announce-strategic-partnership-to-advance-neurodegenerative-disease-research-302307463.html
(archive.org page /
archive.org listing)
Document Date: Nov. 20, 2024, 9:30 p.m. / Source: GlobeNewswire
Activity Class: PartnershipActivity
Partnership:
- Illumina
/ Industry: Biopharmaceutical And Biotech Industry, Biotech And Technology and 8 more
- Myriad Genetics
/ Industry: Biotech And Technology, Genetic Testing Services and 6 more
- Illumina
/ Industry: Biopharmaceutical And Biotech Industry, Biotech And Technology and 6 more
- Myriad Genetics
/ Industry: Biotech And Technology, Genetic Testing Services and 6 more
Document Extract: SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) - Myriad Genetics, Inc. (NASDAQ: MYGN) , a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ: ILMN) , a global leader in DNA sequencing and array - based technologies. Myriad's gold-standard Genomic Instability Score (GIS) to determine Homologous Recombination Deficiency (HRD) will be reported for all samples analyzed with Illumina's updated research assay, TruSight™ Oncology 500 v2 (TSO 500 v2) . Previously, GIS to determine HRD was only available as a separate product. As a result, a broad array of cancer types will receive GIS results and their HRD status. " We are pleased to expand our collaboration with Illumina and combine the two companies' technologies to create what we believe is the most advanced and complete gene panel to enable comprehensive genomic profiling ," said Patrick Burke, PhD, EVP of Strategy and Innovation, Myriad Genetics.
Document Source: https://www.globenewswire.com/news-release/2024/11/20/2984793/15459/en/Myriad-Genetics-Announces-Incorporation-of-its-Proprietary-HRD-platform-in-Illumina-s-Updated-Comprehensive-Gene-Panel-Assay-TruSight-Oncology-500-v2.html
(archive.org page /
archive.org listing)
Document Date: Nov. 19, 2024, 9:05 p.m. / Source: GlobeNewswire
Activity Class: CorporateFinanceActivity
/ Type: Ipo
/ Region: New York City
Vendor:
Document Extract: NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) - Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") today announced an effective date for its previously-announced share consolidation.
Document Source: https://www.globenewswire.com/news-release/2024/11/19/2984021/0/en/Psyence-Biomedical-Announces-Effective-Date-for-1-for-75-Share-Consolidation.html
(archive.org page /
archive.org listing)
Archive.org page links will work if the page has already been archived by archive.org, but we can't guarantee which pages archive.org has archived so far.
Treat sameAsNameOnly relationship as same? Yes
(Turn Off)
Site Stats
| About (includes privacy and cookie notices)
(c) by 1145, 2023-2024. Data licensed under the Open Database License.
Please send an email if you need a non-share-alike license and/or you need API access.